Immune Response Biopharma, Inc. (c) 2010-2020

 

Press Releases TM

Immune Response BioPharma Inc., to Seek FDA Emergency Approval of RespiResponse  IR101C Treatment dose V Beta peptides similar to NeuroVax  for cell mediated responses a white blood cell vaccine.; IRBP enters dialogue with FDA on Expedited Approval. IRBP expects RespiResponse to be 100% effective with 95% Gene Sequencing of Lung & coronavirus Gene types with 95% confidence interval.

March 19th 2020

 

Immune Response BioPharma, Inc. Announces New Whole Killed SARS/Coronavirus Vaccine IR101C Formulation is Complete a new IND will be filed with the FDA and commence work on RespiResponse IR101C. RespiResponse a novel first in class two dose vaccine consists of Depleted GP S spike, Devoid of outter envelope and proteiens chemical killed in beta propiolactone and Gamma Irradiationin in HUT78 cell line in IFA adjuvant, Second Dose a novel Peptide VB V Beta sequenced gene type 100% in IFA adjuvant for cell mediated immune responses and neutralizing enzymes.white blood cell vaccine. IRBP demonstrates our vaccine platform is superior and the global leader in vaccine technology. IRBP will seek Breakthrough desigation with the FDA for RespiResponse a universal Coronavirus vaccine.

January 28th 2020

Immune Response BioPharma Inc. New Whole Killed Ebola Vaccine IR101E Formulation is Complete a New IND submission will be filed with the FDA. EmuneVax consists of Depleted VP24 & VP 40 and outer envelope GP1   &GP2 chemical killed in beta propiolactone & Gamma Irradiation in HUT78 cell line in IFA adjuvant. This is a first in class & best in class vaccine utilizing the original strain from Zaire.  Immune Response  vaccine technology is superior & demonstrates IRBP is the leader in infectious diseases. IRBP will begin planning for Phase I work and manufacturing. The HUT78 cell line has a cell.mediated antibodies against Ebola virus and is difficult to infect & induces cell mediated response s. We believe our Ebola vaccine will become vaccine of choice.

December 30th 2019

 

Immune Response BioPharma Inc. Update on Remune BLA for Adults Remune Delayed as per the FDA "HIV Patients would stop taking their HIV antiviral drugs" if Remune is Approved widely available: IRBP is Exploring all legal avenues to address the CRL including arbitration .IRBP finds the govt's position to be wholly unacceptabe keeping Remune off the market.

N.ov 26th 2019

Immune Response BioPharma, Inc. Provides Update on Remune HIV Vaccine Development: IRBP Expects the FDA to Accept the Remune Pediatric Indication BLA Filing. IRBP Expects Remune for pediatric to be its first approved indication. The FDA OOPD supports the HIV vaccine for children and has designated Remune FDA Orphan drug status, and data verified by NCI lead investigator verfies Remune is safe and effective for pediatric use, Given the design challenges of further pediatric HIV studies feasibility, sufficient data is on hand to garner approval. IRBP is currently addressing technical aspects of the Remune pediatric BLA to ensure a complete application submission, all study line data generated has been processed and analyzed and formatted in eCTD format. IRBP expects acceptance by Q1 2020. a PDUFA Target Date of late 2020 to coincide with manufacturing of new commercial vaccine batches. The Remune BLA PDUFA filing fee is waived for the Remune pediatric indication as an FDA Orphan Designated treatment on Feb 14th 2014 Remune was granted the FDA Orphan drug status endorsement.

October 30th 2019

 

Immune Response BioPharma, Inc. Declares Q1 Dividend of a Minimum $100 per shareholder of Record Feb 1st Payable Feb 15th 2020

October 30th 2019

 

Immune Response BioPharma, Inc. Declares Q4 Dividend of a Minimum $100 per Shareholder of Record December 14th Payable on December 25th 2019

June 3rd 2019

 

Immune Response BioPharma, Inc. Declares Dividend Payable September 14th of $100 Dividend per Shareholder of Record  September 1st 2019

May 24th 2019

 

 

 

 

 

 

 

                        Immune Response BioPharma, Inc.TM Copyright (C) 2010-2020  All Rights Reserved 

                                                                www.immuneresponse.net